Mixed connective tissue disease.
Mixed connective tissue disease (MCTD) is its own entity, defined by very high titers of anti-U1-RNP antibody plus overlapping features of lupus, scleroderma, and myositis. It typically presents with Raynaud's, swollen hands, joint pain, and esophageal dysmotility. Pulmonary arterial hypertension (PAH) is the leading cause of mortality — annual echocardiogram screening matters. Treatment combines hydroxychloroquine, immunosuppression for active features, and PAH-targeted therapy when needed.
The mechanism, the diagnosis defined by one antibody.
MCTD is unique among autoimmune diseases because a specific antibody — anti-U1-RNP — defines it. Four mechanisms drive what patients experience:
Anti-U1-RNP antibody
Very high titers of anti-U1-RNP are the defining feature. The antibody alone doesn't make MCTD — but in the right clinical context, it differentiates MCTD from lupus, scleroderma, or undifferentiated CTD.
Overlap features
Features of lupus (rash, serositis, cytopenias), scleroderma (Raynaud's, sclerodactyly, esophageal dysmotility), and myositis (proximal weakness) coexist. The pattern shifts over time — some patients evolve toward one dominant pattern.
Pulmonary arterial hypertension
PAH is the most clinically important manifestation. It develops in 25–30% of MCTD patients and is the leading cause of mortality. Annual echocardiogram with TR jet assessment is standard of care.
Type I interferon signature
Like lupus and Sjögren's, many MCTD patients have an elevated type I interferon signature. This explains the overlapping skin and serologic features with lupus.
The 4-step plan, applied to MCTD.
Get the right diagnosis
Anti-U1-RNP at high titer (key), ANA pattern (usually speckled), ENA panel to differentiate from lupus and scleroderma, CBC, complement, urinalysis, CK, PFTs with DLCO, echocardiogram with TR jet velocity. Annual PAH screening from diagnosis.
Learn more about labs →Clean up your food
Mediterranean pattern. Small, frequent meals if esophageal dysmotility. Elevate the head of the bed for GERD. Watch sodium and fluid status if cardiac or renal involvement develops.
MCTD & diet →Detox your daily life
Cold protection for Raynaud's is essential. Smoking cessation reduces PAH risk. Fragrance and chemical sensitivities are common — mirror the lupus and scleroderma environment recommendations.
MCTD & environment →Build a stronger body
Gentle aerobic exercise within tolerance. Hand mobility work prevents contractures. If PAH develops, pulmonary rehabilitation is appropriate. Resistance training preserves muscle during steroid courses.
MCTD & exercise →
Go deeper.
Common misconceptions.
"MCTD is just lupus plus scleroderma plus myositis at the same time."
MCTD is its own entity, defined by anti-U1-RNP at high titer. The overlapping features are real — but the antibody profile, treatment response, and PAH risk make it distinct. Calling it 'overlap syndrome' is sometimes used, but MCTD with anti-U1-RNP is a specific diagnosis.
"It's the same as lupus, so the treatment is the same."
Hydroxychloroquine is shared. But MCTD has a higher PAH risk than lupus, lower nephritis risk, and often features that look more like scleroderma — esophageal dysmotility, sclerodactyly. Treatment is tailored to the dominant feature, not generic lupus management.
"If I feel okay, I don't need annual screening."
PAH in MCTD often progresses silently. By the time symptoms appear, significant pulmonary vascular disease has occurred. Annual echocardiogram catches early elevations in pulmonary pressure when treatment is most effective. This isn't optional.
When to see a rheumatologist.
See a rheumatologist if you have:
- Raynaud's phenomenon plus swollen hands ('puffy fingers')
- Joint pain plus a positive ANA at high titer
- Overlapping features of lupus, scleroderma, or myositis
- Confirmed anti-U1-RNP antibody on a previous test
- Unexplained shortness of breath plus Raynaud's
- Esophageal symptoms plus Raynaud's
MCTD often starts with Raynaud's and swollen hands before evolving into more recognizable features. Early evaluation matters — PAH screening starts at diagnosis.
- Sharp GC, et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med, 1972. PubMed 4621694
- Tani C, et al. The diagnosis and classification of MCTD. J Autoimmun, 2014. PubMed 24461386
- Gunnarsson R, et al. Pulmonary hypertension in MCTD. Arthritis Rheum.
- Hajas A, et al. Clinical course and prognosis of MCTD. Rheumatol Int.